Referenties Wegovy® Semaglutide FAQ
Referenties
Wegovy® Semaglutide
Op deze pagina vind je een overzicht van de wetenschappelijke bronnen waarop de informatie in onze FAQ over Wegovy® is gebaseerd. De referenties zijn zorgvuldig geselecteerd uit gerenommeerde medische databases, zoals PubMed en officiële documentatie van overheidsinstanties en fabrikanten.
Alle bronnen zijn afkomstig uit erkende wetenschappelijke publicaties, klinische richtlijnen of productinformatie van de fabrikant (Novo Nordisk). Ze bieden onderbouwde informatie over de werking, veiligheid en inzet van semaglutide bij mensen met overgewicht of obesitas.
📌 Deze referenties zijn bedoeld ter ondersteuning van transparante en betrouwbare voorlichting. Ze vervangen geen medisch advies.
Referenties
1. Obesity, cardiovascular disease, and the promising role of semaglutide: insights from the SELECT trial (2024).Current Problems in Cardiology. Beschikbaar op: https://www.sciencedirect.com/science/article/pii/S0146280623004772
2. Medications for obesity: A review (2024).Journal of the American Medical Association. Beschikbaar op: https://jamanetwork.com/journals/jama/article-abstract/2821290
3. Semaglutide and Tirzepatide Use and Reduction of Cardiovascular Risks in Adults with Overweight and Obesity (2024).Medical Research Archives. Beschikbaar op: https://esmed.org/MRA/mra/article/view/5714
4. Impact of semaglutide on osteoarthritis risk in patients with obesity: A retrospective cohort study (2024).Obesity Science & Practice. Beschikbaar op: https://onlinelibrary.wiley.com/doi/abs/10.1002/osp4.762
5. One-year weight reduction with semaglutide or liraglutide in clinical practice (2024).JAMA Network Open. Beschikbaar op: https://jamanetwork.com/journals/jamanetworkopen/article-abstract/2823644
6. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials (2024).Diabetologia. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11153294/
7. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis (2024). British Medical Journal. Beschikbaar op: https://www.bmj.com/content/384/bmj-2023-076410.long
8. Productkenmerken (2024). Novo Nordisk. Beschikbaar op: https://www.ema.europa.eu/nl/documents/product-information/wegovy-epar-product-information_nl.pdf
9. Wegovy, Werkzame stof: semaglutide (2024).Apotheek.nl. Beschikbaar op: https://www.apotheek.nl/medicijnen/semaglutide?product=wegovy
10. Wegovy (2024). Novo Nordisk. Beschikbaar op: https://www.wegovy.com/
11. Highlights of Prescribing Information (2024). Novo Nordisk. Beschikbaar op: https://www.novo-pi.com/wegovy.pdf#guide
12. Prikinstructies (2024). Novo Nordisk. Beschikbaar op: https://www.wegovy.com/taking-wegovy/how-to-use-the-wegovy-pen.html
13. Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism (2024). Diabetes & Metabolism Journal. Beschikbaar op: https://www.e-dmj.org/journal/view.php?number=2843
14. Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis (2024). Therapeutic Advances in Neurological Disorders. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11437580/
15. Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks (2024). Obesity Pillars. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11404059/
16. Real-World Effectiveness of Semaglutide and Liraglutide for Weight Management in Overweight or Obese Adults with or Without Type-2 Diabetes Mellitus: Emulation of Randomised Clinical Trials Using UK Electronic Medical Records (2024). The Lancet. Beschikbaar op: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4785364
17. Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (2024). The American Journal of Cardiology. Beschikbaar op: https://www.ajconline.org/article/S0002-9149(24)00319-9/fulltext
18. Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure (2024). Journal of the American College of Cardiology. Beschikbaar op: https://www.sciencedirect.com/science/article/pii/S0735109724081920?via%3Dihub
19. Semaglutide and blood pressure: an individual patient data meta-analysis (2024). European Heart Journal. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11458150/
20. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity (2024). JAMA Internal Medicine. Beschikbaar op: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2821080
21. Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology (2024). JAMA Internal Medicine. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11372653/
22. Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity (2024). Diabetes Care. Beschikbaar op: https://diabetesjournals.org/care/article/47/11/1873/156807/Efficacy-and-Safety-of-GLP-1-Medicines-for-Type-2
23. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials (2024). Diabetologia. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11153294/
24. Glucagon‐like peptide‐1 receptor agonists and kidney outcomes (2024). Journal of Diabetes. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11450654/
25. Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide (2024). Cardiovascular Diabetology. Beschikbaar op: https://cardiab.biomedcentral.com/articles/10.1186/s12933-024-02319-7
26. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial (2024). Nature Medicine. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11271387/
27. Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022 (2024). Journal of the American Pharmacists Association. Beschikbaar op: https://www.sciencedirect.com/science/article/pii/S1544319123003096
28. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis (2024). British Medical Journal. Beschikbaar op: https://www.bmj.com/content/384/bmj-2023-076410.long
29. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation (2023). The Lancet. Beschikbaar op: https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00059-7/fulltext
30. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss (2023). Journal of the American Medical Association. Beschikbaar op: https://jamanetwork.com/journals/jama/fullarticle/2810542
31. Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022 (2023). American Pharmacists Association. Beschikbaar op: https://www.sciencedirect.com/science/article/pii/S1544319123003096
32. Obesity Management in Adults: A Review (2023). Journal of the American Medical Association. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11325826/
33. A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications (2023). Life. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC10144237/
34. Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial (2023). Cardiovascular Diabetology. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC9960425/
35. The Cardioprotective Effects of Semaglutide Exceed Those of Dietary Weight Loss in Mice With HFpEF (2023). Journal of the American College of Cardiology. Beschikbaar op: https://www.sciencedirect.com/science/article/pii/S2452302X23002334
36. Beyond glycemia: Comparing tirzepatide to GLP-1 analogues (2023). Reviews in Endocrine and Metabolic Disorders. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC10697893/
37. Glucagon‐like peptide agonists: A prospective review (2023). Endocrinology, Diabetes & Metabolism. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC10782143/
38. The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities (2023). Current Obesity Reports. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC10748770/
39. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation (2023). The Lancet. Beschikbaar op: https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00059-7/fulltext
40. The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis (2023). Endocrine. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC10902041/
41. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss (2023). Journal of the American Medical Association. Beschikbaar op: https://jamanetwork.com/journals/jama/fullarticle/2810542
42. Obesity Management in Adults: A Review (2023). Journal of the American Medical Association. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11325826/
43. Wegovy (semaglutide): a new weight loss drug for chronic weight management (2023). Journal of Investigative Medicine. Beschikbaar op: https://journals.sagepub.com/doi/abs/10.1136/jim-2021-001952
44. Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials (2023). International Journal of Molecular Sciences. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC10341852/
45. Once-weekly semaglutide in adolescents with obesity (2022). New England Journal of Medicine. Beschikbaar op: https://www.nejm.org/doi/full/10.1056/NEJMoa2208601
46. Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis (2022). Endocrine. Beschikbaar op: https://link.springer.com/article/10.1007/s12020-021-02945-1
47. Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity (2022). JAMA Network Open. Beschikbaar op: https://jamanetwork.com/journals/jamanetworkopen/article-abstract/2796491
48. Once-weekly semaglutide for weight management: a clinical review (2022). Journal of Pharmacy Technology. Beschikbaar op: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272494/
49. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases (2022). Journal of the American Medical Association. Beschikbaar op: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2790392
50. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes (2022). Journal of the American Medical Association. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC8753508/
51. Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review (2022). Clinical Epidemiology. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC9738168/
52. Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review (2022). Therapeutic Advances in Chronic Disease. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC9260566/
53. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases (2022). JAMA Internal Medicine. Beschikbaar op: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2790392
54. Clinical review of subcutaneous semaglutide for obesity (2021). Journal of Clinical Pharmacy and Therapeutics. Beschikbaar op: https://onlinelibrary.wiley.com/doi/abs/10.1111/jcpt.13574
55. Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists (2021). Advances in Therapy. Beschikbaar op: https://link.springer.com/article/10.1007/s12325-021-01710-0
56. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial (2021). The Lancet. Beschikbaar op: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00213-0/abstract
57. Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021). The New England Journal of Medicine. Beschikbaar op: https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
58. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (2021). The New England Journal of Medicine. Beschikbaar op: https://www.nejm.org/doi/10.1056/NEJMoa2107519?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
59. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (2021). Journal of the American Medical Association. Beschikbaar op: https://jamanetwork.com/journals/jama/fullarticle/2777025
60. Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance (2020). Clinical Diabetes. Beschikbaar op: https://diabetesjournals.org/clinical/article/38/4/390/35426/Switching-Between-Glucagon-Like-Peptide-1-Receptor
DISCLAIMER
Betrouwbare informatie, verantwoord gedeeld
Samen op weg naar een gezonder leven – medisch verantwoord, effectief en persoonlijk afgestemd
De referentielijst op deze pagina is uitsluitend bedoeld ter informatie. De genoemde artikelen en bronnen zijn gebaseerd op openbaar toegankelijke wetenschappelijke publicaties en hebben betrekking op het gebruik van Wegovy® (semaglutide) bij overgewicht en obesitas.
Hoewel we de grootst mogelijke zorgvuldigheid betrachten bij het selecteren en weergeven van deze informatie, vervangt deze lijst geen medisch advies. Interpretatie van de inhoud en eventuele besluitvorming op basis hiervan dienen altijd plaats te vinden in overleg met een arts of apotheker.
BMI Clinic kan niet aansprakelijk worden gesteld voor eventuele onjuistheden, verouderde informatie of onvolledigheden in de vermelde bronnen.
Voor aanvullende achtergrondinformatie en wetenschappelijke onderbouwing kun je terecht op onze pagina ‘Bronnen’. Hier vind je een overzicht van de literatuur, richtlijnen en onderzoeken die aan onze informatie ten grondslag liggen.
